Navigation Links
Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance

MALVERN, Pa., Jan. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today reported that preliminary fourth quarter 2010 total net revenue was $61.8 million, up 28.7% compared with $48.0 million in the fourth quarter of 2009.  For the full year 2010, preliminary total net revenue was $211.4 million, up 28.9% compared with $164.0 million in 2009.  


"We are energized by the significant progress that Auxilium made in 2010. We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren's contracture, received a positive CHMP opinion with our EU partner, Pfizer, for XIAFLEX for Dupuytren's contracture, and initiated XIAFLEX global phase III clinical trials for Peyronie's disease," said Armando Anido, Chief Executive Officer and President of Auxilium.  "As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth for the Company."

Preliminary Fourth Quarter 2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the quarter ended December 31, 2010: Quarter EndQuarter EndIncrease12/31/201012/31/2009(Decrease)Testim U.S. Revenue

$52.1$42.223.3%Testim Ex – U.S. & Contract Revenue

1.34.9(73.7%)Total Testim Revenue

$53.4$47.113.3%XIAFLEX U.S. Revenue

$7.3n/an/aXIAFLEX Contract Revenue

1.10.922.1%Total XIAFLEX Revenue

$8.4$0.9845.0%Total Worldwide Revenue

$61.8$48.028.7%Contract Revenues represent amortization of previously received upfront and milestone payments.

Preliminary 2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the full year 2010: Year EndYear EndIncrease12/31/201012/31/2009(Decrease)Testim U.S. Revenue

$190.0$152.025.0%Testim Ex – U.S. & Contract Revenue

3.08.5(64.2%)Total Testim Revenue

$193.0$160.520.3%XIAFLEX U.S. Revenue

$14.1n/an/aXIAFLEX Contract Revenue

4.33.622.1%Total XIAFLEX Revenue

$18.4$3.6416.7%Total Worldwide Revenue

$211.4$164.028.9%Contract Revenues represent amortization of previously received upfront and milestone payments.

2011 XIAFLEX Net Revenue GuidanceFor 2011, Auxilium anticipates that 2011 XIAFLEX net revenues will be in the range of $55.0 to $67.0 million, including approximately $50.0 to 60.0 million in U.S. revenue, and $5.0 to 7.0 million in revenue recognized from royalties and milestones under the Pfizer contract.  

Upcoming Investor PresentationAuxilium reported these numbers in advance of a presentation to investors tomorrow, January 11, 2011 at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, when Auxilium's Chief Executive Officer and President, Armando Anido, will outline the Company's strategic priorities.

Mr. Anido will speak at 4:00 p.m. PT (7:00 p.m. ET) tomorrow, and his remarks will be webcast via a link on the "For Investors" section of Mr. Anido will give an overview of the Auxilium current business strategy, which will focus on the following areas:

  • maximizing the value of Testim and XIAFLEX,
  • delivering on the current pipeline,
  • building out the pipeline in specialty therapeutic areas.

  • A PDF of the presentation slides to be used during the remarks is now available on the "For Investors" section of the Auxilium web site under the "Presentations" tab.  A question and answer session will follow tomorrow's presentation and will also be webcast.  The presentation webcast, the presentation slides and the question and answer session webcast can be accessed via a link on the "For Investors" section of the Auxilium web site under the "Events" tab.  The replay will be available for ninety days after the event.

    About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has options to all indications using XIAFLEX for non-topical formulations.  For additional information, visit


    This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 29th Annual J.P. Morgan Healthcare Conference; anticipated net revenues for 2011; and products in development for Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2009 and in Auxilium's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at or by means of Auxilium's home page on the Internet at under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

    In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

    William Q. Sargent, Jr. / V.P., IRAuxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc.(484) 321-5900


    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
    5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
    6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
    7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    10. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    Post Your Comments:
    (Date:10/12/2015)... Oct. 12, 2015  CME Group,s Center for Innovation ... CEO of Theranos, is the 11 th recipient of ... the revolutionary blood diagnostics company, Theranos , to change ... in a new era of preventive care. CME Group will ... Leadership Conference in Naples, Florida , ...
    (Date:10/12/2015)... , October 12, 2015 ... - Pipeline Review, H2 2015 market research report ... R&D pipelines by identifying new targets and MOAs ... . --> ... pipeline spread across 62 pages, analyzing 6 companies, ...
    (Date:10/12/2015)... VALLEY COTTAGE, New York , October 12, 2015 /PRNewswire/ ... Market Insights (FMI) delivers key insights on the global vital ... Signs Monitoring Devices Market: Global Industry Analysis and Opportunity Assessment ... to expand at a healthy CAGR of 9.5% and 9.2% ... period, due to factors, regarding which FMI offers major insights ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... ... October 13, 2015 , ... ActivePDF, a ... PDF automation tool to batch conversions of CAD drawings, plans, and diagrams ... fidelity. , CADConverter eliminates the complexity requirement of specialized applications to view CAD ...
    (Date:10/13/2015)... ... October 13, 2015 , ... ... the world’s first commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a ... and Obstetrics in Vancouver, BC, Canada. , In a presentation entitled: ...
    (Date:10/12/2015)... ... October 13, 2015 , ... ... biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments of Change conference ... the one-of-a-kind awards to Noah Levine and Dean Dauphinais who exemplify the ideals ...
    (Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... According to an article ... data from adults today versus those of a similar group taken in 1988 has shown ... that a person in 2008 with the same diet as someone in 1971 would be ...
    (Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
    Breaking Medicine News(10 mins):